The Danish pharmaceutical company behind the popular weight-loss medications Wegovy and Ozempic announced Tuesday it will collaborate with artificial intelligence leader OpenAI to enhance its operations across multiple business areas.
Novo Nordisk revealed the partnership as it works to catch up with competitor Eli Lilly in the rapidly expanding obesity treatment market, which analysts project could generate over $100 billion annually within the next ten years.
The collaboration will utilize OpenAI’s advanced technology to examine complicated data sets, pinpoint potential new medications, and enhance operational efficiency in production, supply management, distribution, and corporate functions.
The pharmaceutical industry is increasingly turning to artificial intelligence to simplify the more routine aspects of medication development, including locating clinical trial volunteers, choosing research locations, and completing regulatory paperwork. However, industry leaders acknowledge the technology hasn’t yet achieved its full potential in the more challenging area of discovering breakthrough new compounds.
This strategic move comes as Novo Nordisk faces intensified competition from Indianapolis-based Lilly, which recently received U.S. regulatory approval for its weight-loss pill Foundayo. Novo had launched its oral version of Wegovy in January.
While the Danish company did not reveal the financial details of the arrangement, it stated that initial test programs will commence across research, development, manufacturing, and commercial divisions, with complete implementation scheduled for completion by late 2026.
The partnership will also focus on educating Novo’s global employees, enhancing their understanding of AI technology and increasing workplace efficiency across all departments.
“The aim here is not replacing our scientists. It’s about supercharging them,” stated CEO Mike Doustdar during an interview.
Doustdar explained that the collaboration isn’t designed to reduce the company’s existing staff, but rather to enhance productivity and slow down future recruitment needs. He noted that AI will enable workers to perform more quickly and effectively, decreasing the necessity to expand personnel as extensively as previously required. Following his appointment as CEO last year, Doustdar implemented organizational changes that eliminated 9,000 positions.
“AI is reshaping industries and in life sciences, it can help people live better, longer lives,” OpenAI CEO Sam Altman said in a statement. “This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care.”
Novo emphasized that the partnership incorporates comprehensive data security measures, oversight protocols, and human supervision, building upon the company’s current AI projects with other technology partners and research institutions.
